Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings

Rapport Therapeutics, Inc. Common Stock (RAPP) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported RAPP revenue for 2026-06-30 was $0. Net income was -$56.6M. Revenue was down 100.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M. The RAPP filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what Rapport Therapeutics, Inc. Common Stock said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.